Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ADiRaS

Financiado

Cerrado

Alzheimer s Disease Diagnosis by Spectroscopy. Accurate and Non Invasive Medical...

Alzheimer s Disease Diagnosis by Spectroscopy. Accurate and Non Invasive Medical Device for the Diagnosis of Early Stage Alzheimer s Disease. Raman HT is a company expert on Raman Spectroscopy (RS) which has developed a revolutionary medical device to diagnose Alzheimer’s Disease (AD) in blood plasma for the first time. Currently, there are only two accurate methods to... ver más

31/10/2015

RAMAN HEALTH TECHN...

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

RAMAN HEALTH TECHNOLOGIES El desarrollo de una nueva tecnología basada en espectroscopia raman y espectroscopia de infrarrojo para aplicaciones biomédicas, así como e...

TRL 3-4 | 603K€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2015-10-31

PHC-12-2015-1: Clinical research for the validatio...

I+D

Cerrada hace 9 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

RAMAN HEALTH TECHNOLOGIES

50.00K€ | Lider

Proyectos interesantes

RTC-2016-5054-1

Medical Technol...

Data Science

668K€ Cerrado

SensApp

Medical Technol...

Data Science

3M€ Cerrado

ADDIA

Medical Technol...

Data Science

5M€ Cerrado

HEMOSPEC

Medical Technol...

Data Science

5M€ Cerrado

TEC2008-02113

Medical Technol...

Data Science

66K€ Cerrado

TEC2008-02113

Medical Technol...

Data Science

66K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 4 meses Fecha Inicio: 2015-06-04
Fecha Fin: 2015-10-31

Líder del proyecto

RAMAN HEALTH TECHNOLOGIES El desarrollo de una nueva tecnología basada en espectroscopia raman y espectroscopia de infrarrojo para aplicaciones biomédicas, así como e...

TRL 3-4 | 603K€

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Raman HT is a company expert on Raman Spectroscopy (RS) which has developed a revolutionary medical device to diagnose Alzheimer’s Disease (AD) in blood plasma for the first time. Currently, there are only two accurate methods to diagnose AD, expensive, invasive with multiple side effects. Positron Emission Tomography (PET) scans the patient’s brain after being injected with a radioactive marker (cost of €1500) which can cause major allergic reactions. The other method analyzes the cerebrospinal fluid, which requires performing the patient a lumbar puncture. This procedure (relatively expensive, €400) can cause severe headaches, temporary pain of numbness to legs, infections and bleeding into the spinal canal. There are more than 30 million people living with AD in Europe and more than 7 million people that have not received a diagnostic due to the cost and side effects of the current techniques. Without diagnostic, patients lacks of a proper treatment that improves patients life quality ameliorating the symptoms of the disease. The earlier the diagnosis, the earlier the treatment delaying nursery admission. Our solution consists of performing RS onto a sample of blood plasma. It is not invasive, has absolutely no side effects and an estimated selling price of €100. Our solution, making AD diagnosis more affordable, can produce net saving of €2,8bn to the European Healthcare system only delaying institutionalization. Our aim is to bring our solution into the market as a reference diagnostic method for screening patients for Alzheimer’s Disease. Alzheimer Disease is a huge problem that Europe needs to address due to the aging population. By 2050, 50% of the total European population will be over 65 years old and more importantly, 1 out 3 will suffer from Alzheimer’s Disease.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores